Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Newborn blood-spot screening principles
Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Unwell baby while screening is pending or normal
Poor feeding, vomiting, weight loss, jaundice, hypoglycaemia, lethargy, abnormal tone, seizure or breathing change can represent sepsis, endocrine or metabolic disease before screening reports, outside its panel or after a false-negative result.
Action: Assess urgently with neonatal ABCDE and syndrome-directed glucose, gas, bilirubin, ammonia, electrolytes, cultures and other tests, begin indicated sepsis or metabolic treatment and contact specialist services. Do not wait for the blood-spot result and do not interpret a previous normal screen as diagnostic exclusion.
Purpose and principles
Offer and obtain a high-quality newborn blood-spot sample at the correct time, manage prematurity, transfusion, relocation and repeat needs, communicate presumptive-positive results accurately and ensure screening never delays assessment of a symptomatic baby.
Newborn blood-spot screening aims to identify selected serious conditions before symptoms or irreversible harm. Selection depends on evidence that the condition is important, a usable screening marker and effective early intervention exist and the programme's benefits outweigh harms. Screening therefore covers a deliberately limited panel rather than every genetic, metabolic or endocrine disease. A baby can have a serious condition after a normal result, and clinicians must never use screening as a substitute for assessment.
Obtain informed parental choice before sampling. Explain in accessible language which conditions are screened, why day timing matters, what the heel procedure involves, that results can be normal, carrier, presumptive positive or occasionally unclear, and what happens next. Discuss how residual spots and data are stored and used under the current programme information. Use an interpreter when needed. Screening is strongly recommended but is not performed covertly or by asserting that consent is unnecessary.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Paediatrics and child healthOriginal SBA
Responding to a positive screen
A clinically well newborn has a blood-spot marker reported as presumptive positive for an inherited metabolic disease. What is the most appropriate communication and action?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
In England, birth is day 0 and the routine blood-spot sample is offered on day 5, with local arrangements to achieve timely collection and dispatch. A late-presenting baby should be offered screening as soon as practical within the programme's eligibility rules. Other UK nations have their own programme handbooks, panels and logistics; when a baby moves across a border, confirm what was actually sampled and tested rather than assuming UK uniformity.
As of the current England handbook, the panel includes sickle cell disease, cystic fibrosis, congenital hypothyroidism and seven inherited metabolic diseases: phenylketonuria, MCADD, maple-syrup urine disease, isovaleric acidaemia, glutaric aciduria type 1, pyridoxine-unresponsive homocystinuria and hereditary tyrosinaemia type 1. Screening for sickle disease may also identify carrier status and some other haemoglobin patterns. The programme does not screen nationally for every condition, including CAH.
Spinal muscular atrophy remains outside the routine England panel at this dated checkpoint. The UK National Screening Committee announced an England in-service evaluation scheduled to begin in October 2026; Scotland's SMA in-service evaluation began in March 2026. A baby may therefore be offered evaluation sampling in participating areas while the national routine-panel statement remains unchanged. Confirm the current laboratory and local pathway rather than describing an evaluation as universal screening.
Correct identification is a patient-safety step. Match baby identifiers, NHS or community number, date and time of birth, sex or recorded details, gestation, birth weight, mother or parent identifiers and contact information. Record sample date and time, collector, feeding and transfusion details and relevant treatments according to the card. Wrong or missing identifiers can misassign a result or delay a time-critical referral more seriously than a technically imperfect spot.
Use a single-use safety lancet on the approved medial or lateral plantar heel area, avoiding the posterior curvature. Warmth and gravity improve flow. Wipe away the first drop if the programme instruction specifies, then allow a large drop to fall onto the filter paper and fill each required circle completely by soaking from one side. Do not press the card to skin, layer multiple small drops, milk the heel aggressively, use capillary tubes unless specifically approved or contaminate with feed, antiseptic, glove powder or water.
Check the front and back: each spot should fill the printed circle and soak evenly through. Inadequate, compressed, supersaturated, layered, clotted or contaminated spots can be rejected or yield unreliable concentrations. Allow the card to air-dry horizontally at room temperature away from direct sunlight, heaters, fluids and plastic. Send it through the designated transport system promptly, and record dispatch so a missing card triggers a failsafe rather than silence.
Special situations require the current handbook. Very preterm babies need an additional congenital-hypothyroidism sample at the specified age or discharge point because early TSH response can be delayed. Blood transfusion can alter haemoglobin and other markers; obtain a pre-transfusion sample when possible and arrange the laboratory-defined repeat interval after transfusion. Parenteral nutrition can alter amino-acid or acylcarnitine markers. Never invent a repeat date: liaise with the screening laboratory and record the person responsible.
A result above a screening threshold is described as screen positive, suspected or presumptive positive, not confirmed disease. The laboratory activates a condition-specific clinical referral. Contact the family with a planned, compassionate explanation: the result needs urgent diagnostic tests, many screen-positive babies will not ultimately have the condition, and the child should still be assessed for current symptoms. Some pathways begin precautionary feeding or treatment before final confirmation because delay carries high risk.
Results need closed-loop governance. Confirm the laboratory received a satisfactory sample, act immediately on requests for repeat, record the final result in the child health record and ensure parents know how results will be communicated. If parents decline, document the informed discussion, condition-specific decisions where the programme allows them and opportunities to reconsider. When a family moves, the sending and receiving teams must actively reconcile screening status; no result is not equivalent to a normal result.
Screening has false positives, false negatives and incidental information. Prematurity, transfusion, nutrition, sampling quality, biological variation and marker cut-offs influence performance. A symptomatic newborn needs direct tests: prolonged jaundice still requires conjugated bilirubin and thyroid or liver assessment; collapse after fasting still requires glucose, ketones and ammonia; meconium ileus still requires cystic-fibrosis evaluation. Explain this limitation without undermining the very large benefit of timely population screening.
Key points
Newborn blood-spot screening is an offered population screen, not a diagnostic test. Explain purpose, possible results, limitations, storage and follow-up and document informed parental choice or decline.
In England the routine sample is normally taken on day 5, counting birth as day 0; collect promptly when late rather than abandoning screening because the ideal window passed.
The England panel now includes sickle cell disease, cystic fibrosis, congenital hypothyroidism and seven inherited metabolic diseases including hereditary tyrosinaemia type 1; panels and operational details can differ across UK nations.
Spinal muscular atrophy is not part of that routine England panel: an in-service evaluation is scheduled from October 2026, while Scotland's evaluation began in March 2026, so check current local and laboratory coverage as rollout evolves.
Use the current national card and identifiers, confirm baby and mother details and record feeding, gestation, transfusion and other information that changes interpretation.
Warm and position the foot, use the safe heel area, let a large hanging drop soak through each required circle from one side and avoid squeezing, layering, contamination or touching the filter paper.
Inspect both sides for complete saturation, dry horizontally away from heat and contaminants and dispatch through the screened laboratory pathway without avoidable delay.
Indications, selection and cautions
Satisfactory sample
Correct identifiers accompany evenly saturated spots that fill the required circles and have soaked through the filter paper.
Insufficient specimen
Small, pale, incomplete or non-penetrating spots contain too little blood for reliable measurement and require prompt repeat.
Layered or compressed spot
Repeated application to one area or pressing paper against the heel creates uneven analyte concentration and possible rejection.
Presumptive-positive result
A programme marker crosses its referral threshold and activates urgent confirmatory assessment without yet proving the condition.
Special-circumstance baby
Prematurity, transfusion, parenteral nutrition, relocation or previous inadequate collection changes repeat sampling and failsafe needs.
Symptomatic despite screeningRed flag
Clinical deterioration before or after a normal card requires direct emergency investigation rather than waiting for or repeating routine screening.
Red flags requiring action
A clinically unwell baby must be investigated directly even when the blood-spot sample was taken or reported normal.
No laboratory receipt or result in the record is a missing safety step, not evidence of a negative screen.
Wrong identifiers or a card belonging to another baby can cause catastrophic delayed or inappropriate referral.
Method and interpretation
01First-line blood-spot card collectionFirst stepFirst line
Why
Obtain dried capillary blood at the programme time for validated population screening assays.
Interpretation and limitations
A complete, evenly soaked, correctly identified card can enter analysis; the card itself does not diagnose any condition.
02Pre-dispatch quality check
Why
Inspect identifiers, dates, clinical details and both sides of every spot before drying and transport.
Interpretation and limitations
Incomplete saturation, layering, contamination or missing data requires correction or prompt repeat under laboratory advice.
03Laboratory receipt and result tracking
Why
Ensure the sample arrives, is analysable and generates a final or repeat-request outcome linked to the correct child.
Interpretation and limitations
Absence of a recorded outcome activates the failsafe search and cannot be coded as normal screening.
04Condition-specific confirmatory tests
Why
Diagnose or exclude the suspected disorder after a presumptive-positive screen using the programme referral protocol.
Interpretation and limitations
The exact test differs by marker and may include venous hormones, sweat testing, haemoglobin analysis, metabolites, enzyme or genetic studies.
Clinical next steps
01Routine offerExplain, consent and collect on timeFirst stepA newborn reaches the national programme sampling window and is clinically stable.+
1Provide accessible information on conditions, limitations, storage, results and choices and document consent or informed decline.
2Verify identifiers and special circumstances, collect complete single-application spots from the safe heel area and check both sides.
3Air-dry and dispatch promptly, document collection and transport and tell parents how and when the result will be communicated.
02Unsatisfactory or missingClose the screening gap quicklyThe laboratory rejects a specimen, the card is lost, identifiers conflict or no result can be found.+
1Contact the family and screening laboratory promptly and identify why the sample failed or cannot be matched.
2
Risks, monitoring and follow-up
Audit the interval from birth to collection, collection to laboratory receipt and presumptive result to specialist contact.
Track inadequate-sample rates by collector and give technique feedback rather than normalising repeated rejection.
Confirm every child has a final result or documented referral and reconcile unmatched records and duplicate identifiers.
Maintain repeat-sample lists for prematurity, transfusion, parenteral nutrition and early or failed collection with a named owner.
Document parental communication, interpreter use, consent, declined components and any later reconsideration.
For presumptive-positive results, record confirmatory outcome, treatment timing and communication with primary care and child-health records.
Review affected-not-detected cases through programme governance to identify sampling, laboratory, threshold or unavoidable biological causes.
Special situations
Screening is not diagnosis
A positive marker needs confirmation, while a negative result leaves residual risk and many diseases outside the panel.
Day zero is birth
England's day-5 timing counts the day of birth as day 0, preventing a common one-day scheduling error.
One drop should soak through
Layering small drops changes analyte distribution; a free large drop fills each circle more reliably.
Transfusion changes interpretation
Donor cells and dilution can mask haemoglobin and other markers, making pre-transfusion collection and planned repeat crucial.
No result is an active risk
Failsafe systems must find a missing card or family because silence cannot be assumed to mean normal.
Panels evolve
Hereditary tyrosinaemia type 1 now appears in the current England handbook, illustrating why static remembered lists become unsafe.
Common pitfalls
01
Presenting screening as compulsory rather than an informed parental choice.
02
Counting the day of birth as day 1 when scheduling an England day-5 sample.
03
Touching filter paper to the heel or layering several drops in one circle.
04
Dispatching a card with incomplete identifiers or without transfusion and gestation details.
05
Assuming all UK nations use an identical panel and repeat schedule.
06
Calling a presumptive-positive screen a confirmed diagnosis when speaking with parents.
07
Coding an absent result as normal instead of activating the failsafe pathway.
08
Using a normal screen to dismiss jaundice, hypoglycaemia, vomiting or encephalopathy in a sick newborn.
Clinical stateAwaiting review
JurisdictionUnited Kingdom
Premature babies, transfused babies, babies receiving parenteral nutrition and babies moving between services may need extra or repeat samples under national laboratory rules; document ownership explicitly.
A presumptive-positive result means the screening marker crossed a referral threshold, not that the diagnosis is certain. Use the condition-specific urgent clinical referral and confirmatory pathway.
A negative result reduces risk only for the screened targets. If a baby is jaundiced, vomiting, losing weight, hypoglycaemic, encephalopathic or otherwise unwell, investigate and treat the clinical syndrome immediately.
Track every card from offer to laboratory receipt and final result, act on rejected or incomplete samples promptly and use failsafe systems for families who move or cannot be contacted.
An inadequate sample request needs rapid recollection because several screened conditions cause harm before symptoms become obvious.
Transfusion before sampling can mask haemoglobin patterns and alter other results, requiring laboratory-directed repeat planning.
A presumptive-positive result requires the specified clinical pathway and must not be softened into routine follow-up.
Families moving between nations or services need active reconciliation because panel and repeat rules may differ.
05
Special-circumstance repeat sample
Why
Compensate for prematurity, transfusion, parenteral nutrition, early collection or specimen failure using national schedules.
Interpretation and limitations
The screening laboratory determines timing and required targets; repeat ownership must be named and documented.
06Direct diagnostic assessment
Why
Investigate symptoms with bedside and laboratory tests outside the screening process.
Interpretation and limitations
Clinical probability overrides screening reassurance because timing, limited panel and false negatives leave residual disease risk.
EscalationRepeat using corrected technique and details within the programme timeframe and escalate barriers through the child-health failsafe team.
3Track the replacement to receipt and final result and record who remains responsible after discharge or relocation.
03Presumptive positiveMove from screening to diagnosisA marker exceeds the condition-specific referral threshold or the laboratory requests urgent clinical action.+
1Activate the national referral pathway and contact the designated paediatric or specialist team within its required timeframe.
2ConfirmatoryExplain that disease is suspected, not confirmed, assess the baby now and obtain the specified confirmatory specimens.
3Start precautionary treatment or feeding only when the condition pathway recommends it and communicate confirmed or excluded diagnosis compassionately.
04Special circumstanceUse laboratory-defined repeat rulesThe baby is very preterm, transfused, receiving parenteral nutrition, sampled early or moving between programmes.+
1Take any urgent pre-transfusion or baseline sample when feasible and record gestation, transfusion, feeds and treatments accurately.
2Ask the screening laboratory which tests and repeat date apply and avoid relying on memory or another nation's schedule.
3Place the repeat in discharge and transfer documentation, name the collecting team and verify the eventual result through failsafe tracking.
05Symptomatic babyDiagnose disease outside the screenThe newborn becomes unwell before results, after a normal result or with features of a non-panel condition.+
1Use neonatal emergency assessment and obtain direct glucose, gas, ammonia, bilirubin, endocrine, infection or other tests guided by presentation.
2Treat sepsis, adrenal crisis, hypoglycaemia, metabolic catabolism or another emergency immediately and contact specialists.
3Notify screening teams of an affected-not-detected diagnosis where required and review whether sampling, biology or panel limitation explains it.